2. Search Result
Search Result
Results for "

acute respiratory distress syndrome (ARDS)

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99810
    Quisovalimab

    AVTX-002; AEVI 002; SAR 252067

    		 SARS-CoV Cardiovascular Disease
    Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
    Quisovalimab
  • HY-W012683
    Iminodiacetic acid

    		Others Cancer
    Iminodiacetic acid (IDA) is a chelating agent that strongly binds transition metals . Iminodiacetic acid can be used for removal of toxic metal ions from water . Iminodiacetic acid can serve as a biomarker to potentially predict the severity of ARDS (acute respiratory distress syndrome) .
    Iminodiacetic acid
  • HY-154954
    Ogremorphin

    OGM; GPR68-IN-1

    		 GPR68 Inflammation/Immunology
    Ogremorphin (GPR68-IN-1) is a potent GPR68 inhibitor with an EC50of 170 nM. Ogremorphin is extracted from patent WO2020214896 (OGM1), and can be used for autoimmune chronic inflammatory diseases research .
    Ogremorphin
  • HY-150735
    IRAK4-IN-20

    		IRAK Inflammation/Immunology
    IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .
    IRAK4-IN-20
  • HY-145390
    Nrf2 activator-1

    		Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .
    Nrf2 activator-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: